GPI 5693

Drug Profile

GPI 5693

Latest Information Update: 17 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MGI GP
  • Class Neuroprotectants
  • Mechanism of Action Glutamate carboxypeptidase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Cerebral ischaemia; Diabetic neuropathies; Glaucoma; Neuropathic pain; Prostate cancer

Most Recent Events

  • 25 Jul 2006 This programme is still in active development with MGI GP
  • 28 Oct 2005 Guilford Pharmaceuticals is now called MGI GP
  • 05 Oct 2005 Guilford Pharmaceuticals has been acquired by MGI Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top